Ge Long Hui·2025-12-02 12:57Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has received acceptance for the drug registration application of sodium heparin injection from the National Medical Products Administration, indicating a significant step in the company's product development pipeline [1] Group 1: Product Development - The sodium heparin injection is a self-developed chemical drug by the group, intended for multiple medical uses including prevention and treatment of venous thrombosis and pulmonary embolism, and as an anticoagulant in various surgical and medical procedures [1] - As of October 2025, the cumulative R&D investment for this drug by Suzhou Er Ye is approximately RMB 8.61 million (unaudited) [1] Group 2: Market Potential - According to IQVIA CHPA data, the sales revenue of sodium heparin injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 1.386 billion in 2024 [1]